

Supplementary table 4

**Baseline characteristics of the subjects (subgroup by MMSE)**

	MMSE 27 or Lower		MMSE 28 or Higher	
	Donepezil (n=30)	Placebo (n=32)	Donepezil (n=42)	Placebo (n=41)
Age, Yr, mean (SD)	69.0 ( 6.1 )	71.7 ( 5.1 )	65.9 ( 7.9 )	66.9 ( 7.5 )
Female sex, n (%)	17 ( 56.7% )	17 ( 53.1% )	24 ( 57.1% )	22 ( 53.7% )
PD duration, Yr, mean (SD)	8.5 ( 5.1 )	7.6 ( 3.9 )	8.0 ( 4.6 )	8.0 ( 4.6 )
modified H-Y, n (%)				
2.5	15 ( 50.0% )	13 ( 40.6% )	21 ( 50.0% )	25 ( 61.0% )
3	9 ( 30.0% )	14 ( 43.8% )	16 ( 38.1% )	15 ( 36.6% )
4	6 ( 20.0% )	5 ( 15.6% )	5 ( 11.9% )	1 ( 2.4% )
History of psychosis, n (%)	15 ( 50.0% )	8 ( 25.0% )	10 ( 23.8% )	16 ( 39.0% )
ESS, mean (SD)	8.1 ( 4.5 )	6.6 ( 5.1 )	6.2 ( 5.3 )	6.9 ( 5.5 )
UPDRS, mean (SD)				
Part I	1.3 ( 1.0 )	.7 ( .9 )	.5 ( .8 )	.6 ( .9 )
Part II ON	8.2 ( 5.1 )	6.0 ( 5.3 )	5.4 ( 5.0 )	6.4 ( 4.5 )
Part II OFF *	14.5 ( 7.0 )	12.1 ( 7.0 )	13.3 ( 7.2 )	12.3 ( 7.0 )
Part III	23.3 ( 10.3 )	21.9 ( 9.1 )	20.1 ( 11.4 )	21.5 ( 8.9 )
Part IV	3.4 ( 2.8 )	2.6 ( 2.7 )	3.1 ( 2.4 )	2.7 ( 2.0 )
WMS, mean (SD) **				
auditory	43.9 ( 17.0 )	34.2 ( 14.2 )	54.0 ( 19.1 )	53.2 ( 18.5 )
visual	43.2 ( 11.1 )	40.0 ( 13.2 )	52.7 ( 8.7 )	50.8 ( 8.5 )
attention	53.1 ( 11.9 )	52.4 ( 8.3 )	60.0 ( 10.7 )	59.2 ( 7.5 )
delayed recall	50.3 ( 19.9 )	38.6 ( 20.8 )	65.1 ( 16.3 )	64.3 ( 17.3 )
FAB, mean (SD)***	13.7 ( 2.5 )	12.9 ( 2.0 )	15.2 ( 2.2 )	14.5 ( 2.0 )
Dopaminergic agonist user, n (%)	19 ( 63.3% )	18 ( 56.3% )	29 ( 69.0% )	34 ( 82.9% )
amantadine user, n (%)	6 ( 20.0% )	5 ( 15.6% )	12 ( 28.6% )	10 ( 24.4% )
Apolipoprotein E4, n (%) ***	11 ( 42.3% )	6 ( 22.2% )	10 ( 28.6% )	10 ( 27.0% )

\* n = 14 (MMSE < 28, donepezil), 17 (MMSE < 28, placebo), 27 (MMSE 28 or higher, donepezil), 22 (MMSE 28 or higher, placebo)

\*\* n = 28 (MMSE <28, donepezil), 31 (MMSE <28, placebo), 40 (MMSE 28 or higher, donepezil), 41 (MMSE 28 or higher, placebo)

\*\*\* n = 29 (MMSE <28, donepezil), 32 (MMSE <28, placebo), 41 (MMSE 28 or higher, donepezil), 41 (MMSE 28 or higher, placebo)

\*\*\* n = 26 (MMSE <28, donepezil), 27 (MMSE <28, placebo), 35 (MMSE 28 or higher, donepezil), 37 (MMSE 28 or higher, placebo)